COVID-19NCT06452108
Community Perception on COVID-19 Prevention and Control
An observational study of COVID-19, run by University of Edinburgh at 1 site in Pakistan.
Trial summary
In times whereby COVID-19 is rapidly spreading, research on the epidemiological, diagnostic, clinical and social aspects of the illness has been highlighted as important as there is very limited information of this disease in all these aspects. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- COVID-19
- How many people
- 2,651 participants
- Where
- 1 sitePakistan
- Study dates
- 4 Apr 2020to 31 Dec 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Inclusion criteria will be men and women over the age of 18 years residing within the following administrative units of Pakistan: * Islamabad (federal capital) * Punjab * Sindh * Baluchistan * Khyber Pakhtun Khwah Upon first contact with the respondents, we will ask if they would like to take part in the study. For those who have agreed to take part in the study, we will read the participant information sheet and ask the respondents to give us their verbal consent.
Who may be able to join
- Inclusion criteria will be men and women over the age of 18 years.
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Community Perception on Effective Approaches to Promote Acceptance and Adherence to Public Health Measures for COVID-19 Prevention and Control
In times whereby COVID-19 is rapidly spreading, research on the epidemiological, diagnostic, clinical and social aspects of the illness has been highlighted as important as there is very limited information of this disease in all these aspects. Keeping this in view, WHO has published a roadmap for global research referred to as the 2019 novel Coronavirus Global research and innovation forum: towards a research roadmap13. This document has identified around 34 knowledge gaps which need to be addressed in order to learn more about this illness. One of these gaps indicates that disease transmission is driven by both social and biological factors. Social sciences research, thus, can play a very important role in combating this illness. It can bring rich insights into social, behavioral and contextual aspects of communities, societies and populations affected by COVID-19 to enhance acceptability of and adherence to evidence-based public health measures for successful infection prevention and control (IPC).
Read the detailed description
While much of published research regarding COVID-19 has focused on virology, epidemiology and clinical aspects of COVID-19, commentaries, editorials and letters from sociologists, economists and political scientists have highlighted the social impacts of COVID-19, particularly in China. It is, therefore, very important to explore the community perception of the impact this illness is having on the lives of the general public and the practices which they are adopting to contain the disease. These kinds of insights are important for national public health officials looking to implement control measures that may have clear biomedical rationale but require social and behavioral cooperation from citizens to be effective. Rapid identification of these impacts and research is necessary to generate evidence that can inform approaches to mitigate them. This is because public health authorities are not operating in a vacuum, but in already functioning communities and societies with established socio-cultural systems that include different forms of authority, organization and coping and resilience mechanisms to face adversity. Local knowledge and perception of COVID-19 will, therefore, drive local reactions and responses.
Among all the affected countries, Pakistan has also been affected with more than 76,398 confirmed cases and 1621 deaths till June 2, 202014. In March 2020, the government of Pakistan published a National Action Plan (NAP) on COVID-19 to deal with the illness. Among the important factors that focused on COVID-19, one was the generation of evidence to guide better decision making15. Pakistani communities are very diverse in their cultural and social norms and therefore their response to COVID-19 might also be varied. It is, therefore, important to identify the perception, practice and attitude of the community towards containing this disease. This is because clinical management of COVID-19 patients can only be effective if the healthcare system is not overburdened with a constant flow of patients which is increasing day by day. This increase in the percentage of patients is directly proportional to the measures that the community takes to contain the disease.
STUDY DESIGN A descriptive study design with a cross-sectional approach will be adopted whereby nationally representative sample of respondents (based on latest census 2018) across Pakistan through Computer Assisted Telephonic Interviewing (CATI) will be interviewed. CATI is a research and analysis program with no direct human-human interaction whereby data is collected telephonically through tablets/computers with incorporated questionnaires with logical checks. CATI has the capacity of respondent randomization, full central server quota control, sample management, appointments and automatic dialing.
Upon local ethical clearance, development of the questionnaire, its pre-testing and development of its CATI based version, the enumerators will be trained remotely through , Skype or MS teams. Skype will be used as a priority. These enumerators are our collaborator International Research Force (IRF)'s trained data collectors.
For this particular study the enumerators will be trained on obtaining consent from the respondents followed by data collection on the questionnaire. They will:
- Identify themselves promptly
- Clearly state the purpose of research
- Ensure that participation is voluntary based on information about the purpose and nature of the research that is adequate and not misleading
- Respect the right of data subjects to refuse requests to participate in research
Each enumerator has a company laptop with headphones and microphone to conduct the data collection. The enumerator, therefore, has the capacity to collect data, while working from home through these systems connected to the central server that will automatically dial numbers once logged in (each enumerator having a separate login and password).
Numbers will be automatically dialled from an already available panel of respondents who have already agreed to take part in public opinion based surveys with frequency of interviewing @ once a month. The system will be using the principle of random digital dialing (RDD) to ensure random sampling. The system will automatically dial these numbers ensuring that none of the enumerators will have access to the phone numbers of the respondents. . Respondents will be interviewed on knowledge of COVID-19, social norms to prevention, risk of disease, and important factors to promote adherence to the preventive measures. We shall also be collecting demographic information including age, gender, province , SES and level of education. Monitoring of the data collection process will be conducted through an online dashboard by the project manager. The manager will access the dashboard and observe the performance of each enumerator by noting the number of calls made per day, and the disposition status given by the enumerator against each call including the number of successful interviews, number of incomplete interviews, number of refusals, not responding numbers etc. Data entered in the computer system by each enumerator shall be sent to the central server which can be accessed remotely and extracted by the data manager for analysis and reporting.
IDENTIFYING PARTICIPANTS Participants will be approached through RDD through a database within the International Research Force (IRF) CATI system.
CONSENTING PARTICIPANTS Verbal consent will be obtained from all the participants before the interview. Interviewer will read out the participant information sheet to the respondent and will record the responses in the form. The information sheet includes statements on voluntary participation with option to discontinue at any point of the study with no penalty to the participants. Any queries from the participants regarding the study will be resolved prior to taking the consent. If the respondent agrees to be interviewed upon giving consent he/she will be interviewed otherwise he/she will be given 2-3 days to agree to participate upon which the enumerator will call the respondent to determine consent which will be taken verbally and recorded.
Withdrawal of Study Participants Participants will be free to withdraw from the study at any point with or without providing any reason or he/she can be a withdrawn by the Investigator. If a withdrawal occurs, the primary reason for withdrawal will be documented in the participant's case report form or marked unspecified if no reason was given by the participant.
DATA COLLECTION
The IRF CATI software will enable data collection through:
- Creating lists of leads from the panel which can be used for dialling automatically.
- Calling respondents through RDD whereby the interviewer does not need to dial in the numbers.
- Scheduling the system for follow up calls for respondents unavailable in previous attempts.
- Allowing live data entry into the software.
- Incorporating automatic logical skips and data coding checks to provide error free or incomplete data entry.
- Providing disposition status.
- Providing minute by minute status of total and per-hour results-by-interviewer, results per day or per attempt, the number of telephone numbers still active, cooperation rates, and more.
Data Management Personal Data
The following personal data will be collected as part of the research:
- Age
- Provincial
- Gender
- Level of education
- Socioeconomic class
Personal data will be stored for up to 5 years after completion of the study after which it will be destroyed. Once the data is obtained from the IRF CATI system for analysis, it will be deleted from there.
Storage:
All data (raw and anonymized) in the form of excel sheets and SPSS data files along with preliminary reports will be stored in password protected folders and computers with access to authorized members of the research team only.
Backup:
3 copies of the original data will be created and stored on different locations. Original copy will be stored on the password protected computer of the data manager. This will be backed up fortnightly on the main server located at the central field office and on cloud storage.
Anonymized, non-identifiable data will also be stored on the University of Edinburgh file store. This is high quality, enterprise-class storage with guaranteed backup and resilience. The data is automatically replicated to an off-site disaster facility and backed up with a 60-day retention period, with 10 days of file history visible online.
File naming:
Files will be named as per the standard naming convention of the organization i.e. organization name project ID_type of data file e.g. MCNHRN_RES007_excelsheet.txt
Organization:
Password protected folders will be created for each data file. Files will be placed in their respective folders.
Transfer of Data All data collected or generated by the study (including personal data) will not be transferred outside the research site except to the University of Edinburgh data repository (DataShare) whereby only anonymized, non-identifiable data will be stored.
Non-identifiable data from this project may be stored in a research data repository at the University of Edinburgh to allow knowledge sharing and learnings about this study. The University of Edinburgh provides its researchers (and their collaborators) two services for sharing and archiving of data which will be used for their information. There is an open access repository for anonymized data, which means that all non-identifiable data is freely available. For sensitive information a secure repository is used which can only be accessed by approved researchers who have undergone a rigorous application and review process.
Data Controller The data controller is University of Edinburgh.
- Conditions
- COVID-19
- Keywords
- community perception, Pakistan, COVID-19 prevention, COVID-19 control
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Islamabad (Federal) site | Determine community perspective on COVID-19 for identification of relevant, feasible, and effective approaches to promote acceptance, uptake, and adherence of public health measures for COVID-19 prevention and control in Pakistan through generation of high-quality evidence to achieving the goals of the NAP. | |
| Punjab site | Determine community perspective on COVID-19 for identification of relevant, feasible, and effective approaches to promote acceptance, uptake, and adherence of public health measures for COVID-19 prevention and control in Pakistan through generation of high-quality evidence to achieving the goals of the NAP. | |
| Sindh site | Determine community perspective on COVID-19 for identification of relevant, feasible, and effective approaches to promote acceptance, uptake, and adherence of public health measures for COVID-19 prevention and control in Pakistan through generation of high-quality evidence to achieving the goals of the NAP. | |
| Baluchistan site | Determine community perspective on COVID-19 for identification of relevant, feasible, and effective approaches to promote acceptance, uptake, and adherence of public health measures for COVID-19 prevention and control in Pakistan through generation of high-quality evidence to achieving the goals of the NAP. | |
| KPK site | Determine community perspective on COVID-19 for identification of relevant, feasible, and effective approaches to promote acceptance, uptake, and adherence of public health measures for COVID-19 prevention and control in Pakistan through generation of high-quality evidence to achieving the goals of the NAP. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of respondents who correctly answer questions related to COVID-19 transmission, prevention, symptoms and treatment
This will measure knowledge regarding COVID-19 transmission, prevention, symptoms and treatment
Measured: 12 months
Percentage of respondents who adhered to recommended COVID-19 preventive measures
This will measure practices such as mask-wearing, hand hygiene, social distancing, and vaccination uptake
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2024
- Study start4 Apr 2020
- Primary completion30 Apr 2021
- Study completion31 Dec 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 2,651 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Edinburgh
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Dr Tabish Hazir, MBBS, FRCPCH, Principal investigator, Maternal Neonatal Child Health Research Network
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06452108
- Sponsor's protocol ID
- 168/301/223
- Status last verified
- Jun 2024
- First submitted
- 7 Jun 2024
- Last updated
- 13 Jun 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jun 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Community Perception on Effective Approaches to Promote Acceptance and Adherence to Public Health Measures for COVID-19 Prevention and Control
- ClinicalTrials.gov ID
- NCT06452108
- Acronym / sponsor ID
- 168/301/223
- Conditions
- COVID-19
- Keywords
- community perception, Pakistan, COVID-19 prevention, COVID-19 control
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 2,651 participants (actual)
- Lead sponsor
- University of EdinburghUniversity, hospital or other
- Study start
- 4 Apr 2020 (actual)
- Primary completion
- 30 Apr 2021 (actual)
- Study completion
- 31 Dec 2021 (actual)
- First posted
- 11 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In times whereby COVID-19 is rapidly spreading, research on the epidemiological, diagnostic, clinical and social aspects of the illness has been highlighted as important as there is very limited information of this disease in all these aspects. Keeping this in view, WHO has published a roadmap for global research referred to as the 2019 novel Coronavirus Global research and innovation forum: towards a research roadmap13. This document has identified around 34 knowledge gaps which need to be addressed in order to learn more about this illness. One of these gaps indicates that disease transmission is driven by both social and biological factors. Social sciences research, thus, can play a very important role in combating this illness. It can bring rich insights into social, behavioral and contextual aspects of communities, societies and populations affected by COVID-19 to enhance acceptability of and adherence to evidence-based public health measures for successful infection prevention and control (IPC).
Detailed description
While much of published research regarding COVID-19 has focused on virology, epidemiology and clinical aspects of COVID-19, commentaries, editorials and letters from sociologists, economists and political scientists have highlighted the social impacts of COVID-19, particularly in China. It is, therefore, very important to explore the community perception of the impact this illness is having on the lives of the general public and the practices which they are adopting to contain the disease. These kinds of insights are important for national public health officials looking to implement control measures that may have clear biomedical rationale but require social and behavioral cooperation from citizens to be effective. Rapid identification of these impacts and research is necessary to generate evidence that can inform approaches to mitigate them. This is because public health authorities are not operating in a vacuum, but in already functioning communities and societies with established socio-cultural systems that include different forms of authority, organization and coping and resilience mechanisms to face adversity. Local knowledge and perception of COVID-19 will, therefore, drive local reactions and responses.
Among all the affected countries, Pakistan has also been affected with more than 76,398 confirmed cases and 1621 deaths till June 2, 202014. In March 2020, the government of Pakistan published a National Action Plan (NAP) on COVID-19 to deal with the illness. Among the important factors that focused on COVID-19, one was the generation of evidence to guide better decision making15. Pakistani communities are very diverse in their cultural and social norms and therefore their response to COVID-19 might also be varied. It is, therefore, important to identify the perception, practice and attitude of the community towards containing this disease. This is because clinical management of COVID-19 patients can only be effective if the healthcare system is not overburdened with a constant flow of patients which is increasing day by day. This increase in the percentage of patients is directly proportional to the measures that the community takes to contain the disease.
STUDY DESIGN A descriptive study design with a cross-sectional approach will be adopted whereby nationally representative sample of respondents (based on latest census 2018) across Pakistan through Computer Assisted Telephonic Interviewing (CATI) will be interviewed. CATI is a research and analysis program with no direct human-human interaction whereby data is collected telephonically through tablets/computers with incorporated questionnaires with logical checks. CATI has the capacity of respondent randomization, full central server quota control, sample management, appointments and automatic dialing.
Upon local ethical clearance, development of the questionnaire, its pre-testing and development of its CATI based version, the enumerators will be trained remotely through , Skype or MS teams. Skype will be used as a priority. These enumerators are our collaborator International Research Force (IRF)'s trained data collectors.
For this particular study the enumerators will be trained on obtaining consent from the respondents followed by data collection on the questionnaire. They will:
- Identify themselves promptly
- Clearly state the purpose of research
- Ensure that participation is voluntary based on information about the purpose and nature of the research that is adequate and not misleading
- Respect the right of data subjects to refuse requests to participate in research
Each enumerator has a company laptop with headphones and microphone to conduct the data collection. The enumerator, therefore, has the capacity to collect data, while working from home through these systems connected to the central server that will automatically dial numbers once logged in (each enumerator having a separate login and password).
Numbers will be automatically dialled from an already available panel of respondents who have already agreed to take part in public opinion based surveys with frequency of interviewing @ once a month. The system will be using the principle of random digital dialing (RDD) to ensure random sampling. The system will automatically dial these numbers ensuring that none of the enumerators will have access to the phone numbers of the respondents. . Respondents will be interviewed on knowledge of COVID-19, social norms to prevention, risk of disease, and important factors to promote adherence to the preventive measures. We shall also be collecting demographic information including age, gender, province , SES and level of education. Monitoring of the data collection process will be conducted through an online dashboard by the project manager. The manager will access the dashboard and observe the performance of each enumerator by noting the number of calls made per day, and the disposition status given by the enumerator against each call including the number of successful interviews, number of incomplete interviews, number of refusals, not responding numbers etc. Data entered in the computer system by each enumerator shall be sent to the central server which can be accessed remotely and extracted by the data manager for analysis and reporting.
IDENTIFYING PARTICIPANTS Participants will be approached through RDD through a database within the International Research Force (IRF) CATI system.
CONSENTING PARTICIPANTS Verbal consent will be obtained from all the participants before the interview. Interviewer will read out the participant information sheet to the respondent and will record the responses in the form. The information sheet includes statements on voluntary participation with option to discontinue at any point of the study with no penalty to the participants. Any queries from the participants regarding the study will be resolved prior to taking the consent. If the respondent agrees to be interviewed upon giving consent he/she will be interviewed otherwise he/she will be given 2-3 days to agree to participate upon which the enumerator will call the respondent to determine consent which will be taken verbally and recorded.
Withdrawal of Study Participants Participants will be free to withdraw from the study at any point with or without providing any reason or he/she can be a withdrawn by the Investigator. If a withdrawal occurs, the primary reason for withdrawal will be documented in the participant's case report form or marked unspecified if no reason was given by the participant.
DATA COLLECTION
The IRF CATI software will enable data collection through:
- Creating lists of leads from the panel which can be used for dialling automatically.
- Calling respondents through RDD whereby the interviewer does not need to dial in the numbers.
- Scheduling the system for follow up calls for respondents unavailable in previous attempts.
- Allowing live data entry into the software.
- Incorporating automatic logical skips and data coding checks to provide error free or incomplete data entry.
- Providing disposition status.
- Providing minute by minute status of total and per-hour results-by-interviewer, results per day or per attempt, the number of telephone numbers still active, cooperation rates, and more.
Data Management Personal Data
The following personal data will be collected as part of the research:
- Age
- Provincial
- Gender
- Level of education
- Socioeconomic class
Personal data will be stored for up to 5 years after completion of the study after which it will be destroyed. Once the data is obtained from the IRF CATI system for analysis, it will be deleted from there.
Storage:
All data (raw and anonymized) in the form of excel sheets and SPSS data files along with preliminary reports will be stored in password protected folders and computers with access to authorized members of the research team only.
Backup:
3 copies of the original data will be created and stored on different locations. Original copy will be stored on the password protected computer of the data manager. This will be backed up fortnightly on the main server located at the central field office and on cloud storage.
Anonymized, non-identifiable data will also be stored on the University of Edinburgh file store. This is high quality, enterprise-class storage with guaranteed backup and resilience. The data is automatically replicated to an off-site disaster facility and backed up with a 60-day retention period, with 10 days of file history visible online.
File naming:
Files will be named as per the standard naming convention of the organization i.e. organization name project ID_type of data file e.g. MCNHRN_RES007_excelsheet.txt
Organization:
Password protected folders will be created for each data file. Files will be placed in their respective folders.
Transfer of Data All data collected or generated by the study (including personal data) will not be transferred outside the research site except to the University of Edinburgh data repository (DataShare) whereby only anonymized, non-identifiable data will be stored.
Non-identifiable data from this project may be stored in a research data repository at the University of Edinburgh to allow knowledge sharing and learnings about this study. The University of Edinburgh provides its researchers (and their collaborators) two services for sharing and archiving of data which will be used for their information. There is an open access repository for anonymized data, which means that all non-identifiable data is freely available. For sensitive information a secure repository is used which can only be accessed by approved researchers who have undergone a rigorous application and review process.
Data Controller The data controller is University of Edinburgh.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Islamabad (Federal) site | – | –Determine community perspective on COVID-19 for identification of relevant, feasible, and effective approaches to promote acceptance, uptake, and adherence of public health measures for COVID-19 prevention and control in Pakistan through generation of high-quality evidence to achieving the goals of the NAP. |
| Punjab site | – | –Determine community perspective on COVID-19 for identification of relevant, feasible, and effective approaches to promote acceptance, uptake, and adherence of public health measures for COVID-19 prevention and control in Pakistan through generation of high-quality evidence to achieving the goals of the NAP. |
| Sindh site | – | –Determine community perspective on COVID-19 for identification of relevant, feasible, and effective approaches to promote acceptance, uptake, and adherence of public health measures for COVID-19 prevention and control in Pakistan through generation of high-quality evidence to achieving the goals of the NAP. |
| Baluchistan site | – | –Determine community perspective on COVID-19 for identification of relevant, feasible, and effective approaches to promote acceptance, uptake, and adherence of public health measures for COVID-19 prevention and control in Pakistan through generation of high-quality evidence to achieving the goals of the NAP. |
| KPK site | – | –Determine community perspective on COVID-19 for identification of relevant, feasible, and effective approaches to promote acceptance, uptake, and adherence of public health measures for COVID-19 prevention and control in Pakistan through generation of high-quality evidence to achieving the goals of the NAP. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Inclusion criteria will be men and women over the age of 18 years residing within the following administrative units of Pakistan: * Islamabad (federal capital) * Punjab * Sindh * Baluchistan * Khyber Pakhtun Khwah Upon first contact with the respondents, we will ask if they would like to take part in the study. For those who have agreed to take part in the study, we will read the participant information sheet and ask the respondents to give us their verbal consent.
Key inclusion criteria (1 listed)
- Inclusion criteria will be men and women over the age of 18 years.
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Percentage of respondents who correctly answer questions related to COVID-19 transmission, prevention, symptoms and treatment
Time frame: 12 months
This will measure knowledge regarding COVID-19 transmission, prevention, symptoms and treatment
Percentage of respondents who adhered to recommended COVID-19 preventive measures
Time frame: 12 months
This will measure practices such as mask-wearing, hand hygiene, social distancing, and vaccination uptake
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jun 2024.
Related trials for COVID-19
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Not yet recruitingPhase 3
Dapagliflozin for Long COVID Syndrome
COVID - 19, Long COVID Syndrome
RecruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruitingObservational study
Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma
Asymptomatic COVID-19 Infection Laboratory-Confirmed, Symptomatic COVID-19 Infection Laboratory-Confirmed
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dr Tabish Hazir, MBBS, FRCPCH principal investigator
Maternal Neonatal Child Health Research Network
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19, run by University of Edinburgh at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of respondents who correctly answer questions related to COVID-19 transmission, prevention, symptoms and treatment (time frame: 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jun 2024.